People
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Governance Grade: B−
Sagility passes the basic SEBI tests — 5 of 9 directors are independent, committees are properly constituted, and disclosure quality is clean — but the company is owned by a private-equity exit machine. EQT/Sagility B.V. has already cut its stake from 95%+ pre-IPO to 50.95% in eighteen months, the IPO and both subsequent sell-downs raised zero primary capital, and no insider other than the promoter owns disclosed equity. The board is credentialed and the CEO is competent; the problem is alignment, not integrity.
Governance Grade
Skin-in-the-Game Score (1-10)
Core tension: the controlling shareholder is a 2014-vintage PE fund mid-way through a planned exit. Every block deal increases free float but shrinks the entity that has historically aligned management. There is no founder, no domestic promoter family, and no disclosed executive shareholding to take EQT's place as the long-term anchor.
1. The People Running This Company
Five names matter. The rest is depth.
The CEO is a known quantity. Ramesh Gopalan ran this exact business when it sat inside Hinduja Global Solutions, was carved out alongside the asset in the 2021 EQT transaction, and was formally elevated from interim leadership to MD/Group CEO on 24-Jun-2024 — five months before listing. That is short tenure as a public-company CEO but long tenure on the underlying business. There are no disclosed prior controversies, regulatory actions, or litigation against him in the data set.
The two promoter-nominee directors — Mahtani (BPEA) and Gopalakrishnan — are present to represent EQT's economic interest, not to challenge it. They take no remuneration and will rotate off as EQT exits. The independence calculus on this board therefore depends almost entirely on the five formally independent directors.
2. What They Get Paid
The structure is unusual for a recently-IPOed Indian IT/BPM company: pay is 50/50 fixed-and-variable cash, with no listed-stock equity granted to the CEO in FY25. That is a one-year artefact — the company listed in Nov 2024 and the ESOS 2026 scheme (proposed May 2026 board meeting, up to 3.30% dilution subject to shareholder approval) will be the first material public-market equity instrument.
Cash pay is reasonable. $0.80M for the CEO of a ~$0.6B-revenue listed services company is below Coforge, Persistent, or Mphasis CEO pay and broadly in line with mid-cap IT-BPM benchmarks. The 220× pay-ratio to median employee is high for India but is mechanical — the median is dragged down by a 46,000-strong agent workforce in India and the Philippines (median compensation ~$3,654 per year).
The flag is timing: the CEO's first equity grant will be priced after EQT has continued to exit and the stock has potentially repriced. Watch how the ESOS 2026 strike is set and whether vesting includes performance hurdles or pure time-based vesting.
3. Are They Aligned?
Three pieces: an ongoing private-equity exit, no executive personal stake, and shareholder-friendly capital return so far.
Ownership: an organised PE exit
Three liquidity events, zero dollars raised for the company. The IPO was a pure secondary OFS, and so were both 2025 block deals. Every share sold above paid out EQT, not Sagility. The company funded debt repayment, BroadPath acquisition, and dividends entirely from its own cash flow — which is actually a positive on operating quality, but a warning sign on intent: a controlling owner using the public market exclusively to exit.
Insider buying / selling: silence except for the promoter
Trendlyne SAST/PIT filings show no executive or director own-account purchases or sales since 2015 under SEBI PIT regulations. The only insider activity on record is Sagility B.V.'s two sell-downs above. No executive has bought a single share in the open market post-IPO.
That silence cuts both ways. No executive is dumping shares; but no executive has meaningful personal capital at risk either — they collect salary and bonus, and will collect ESOPs once the 2026 plan is approved. There is no founder-style alignment.
Dilution and equity grants
The 3.30% ESOS pool is large for a single grant but reasonable as a multi-year reserve for a 46,000-employee company. Until vesting and strike-pricing details are filed, it is the single most important governance disclosure to watch through 2026-27.
Related-party behaviour
Sagility B.V. (Netherlands, EQT-owned) is the promoter; Sagility Health LLC (US) and other subsidiaries are nested under it. The standard RPT risks in this structure are management-fee leakage, trademark-license charges, and shared-services cross-bills. None of these surfaced as material in the disclosures or in independent commentary through Mar-2026. The Audit Committee is independent-majority and the policy was updated to the post-1-Apr-2023 SEBI LODR standard.
Capital allocation
Capital allocation is shareholder-friendly in stated intent: deleverage, modest dividend ($0.0018 total FY26 per share), continued tuck-in acquisitions. The CEO has been explicit that growth in payouts will come "though there's no firm commitment." Total FY26 cash returned to shareholders is modest (~0.4% yield at current price) but defensible while debt is still being retired.
Skin-in-the-game score: 5/10
The 5/10 reflects a control-shareholder that is genuinely aligned today but on a stated path to becoming an ordinary minority. The score will mechanically drift down each time EQT places a block, unless and until a domestic strategic or insurer takes a 5%+ position as anchor.
4. Board Quality
Real, not just formal, independence. Of the five independent directors:
- Dr. William Winkenwerder Jr. brings the strongest single credential: ex-Assistant Secretary of Defense for Health Affairs, ex-CEO of Highmark, and a long career in US payer governance. For a company whose entire revenue base is US payers, this is the single most valuable seat.
- Ginger Dusek adds US payer operational expertise from inside the industry.
- Anil Chanana and Venkat Krishnaswamy carry the finance/audit credentials; Chanana's profile aligns with finance-leadership tenure at a large Indian IT services firm.
- Dr. Shalini Sarin rounds out the board with sustainability and policy experience.
The principal gap is technology and cybersecurity. For a company selling generative-AI services into HIPAA-regulated US payer workflows, a dedicated tech/data-protection independent voice would meaningfully strengthen the board. Current expertise on this dimension is thin.
The principal strength beyond independence is committee composition: Audit and Nomination/Remuneration are independent-majority and chaired by independents — not always the case in promoter-controlled Indian companies.
Board Size
Independent
Women Directors
Avg Tenure (yrs)
Avg Age (yrs)
One female independent director (Dr. Sarin) — meets but does not exceed the SEBI minimum. A second would be a reasonable expectation for FY27 given the board's stated emphasis on diversity in the corporate governance report.
5. The Verdict
Governance Grade
Skin in the Game (/10)
Promoter (%)
Independent (%)
Grade: B−. Properly constituted board, credentialed independents in the right domains, clean RPT and disclosure track record, sensible cash compensation, and shareholder-friendly capital allocation. The deductions are real but specific.
Strongest positives
- Independent-majority Audit and NRC, chaired by independents.
- A genuinely useful payer-domain independent in Winkenwerder.
- No insider selling outside the promoter; no executive perks, related-party leakage, or compliance flags surfaced in the data set.
- CEO is the operator who built the business, not a hired manager.
Real concerns
- The promoter is a PE fund whose exit is the operating model. Two block deals in twelve months took its stake from 82% to 51%. The third is a matter of when, not if.
- No executive owns disclosed listed equity. ESOS 2026 has not yet been structured.
- Board tech / cyber expertise is thin for a company selling GenAI into HIPAA-regulated US payer workflows.
- The CFO transitioned during the sell-down window — operationally minor, but a continuity question.
What would move the grade
- Upgrade to B/B+ if the ESOS 2026 strike is set at a meaningful premium with performance-vesting tied to revenue or margin, and at least one executive starts buying on the open market.
- Downgrade to C+ if the next EQT exit is followed by no anchor replacement, a related-party transaction surfaces, or the ESOS is granted at a deep discount without performance hurdles.
The pivotal variable is what replaces EQT. A 5%+ position taken by a domestic strategic, a US healthcare partner, or a long-term institutional anchor in the next OFS would strengthen the alignment story. If the next block distributes to passive funds, the board becomes the sole governance check — the directors above are credentialed enough, but the company is still too young to know how that holds up under stress.